Xconomy: Seattle Genetics "Empowered Antibody" Shines at Blood Disease Meeting
Summary
Seattle Genetics “Empowered Antibody” Shines at Blood Disease Meeting (Page 2 of 2) so it’s impossible to accurately compare it to how patients would have done on other treatment.Based on this data, Seattle Genetics plans to start a more rigorous final-stage clinical trial program in the first half of 2009 that could lead to FDA approval to market SGN-35 as its first commercial product.Getting the clinical trial plan properly designed to make sure SGN-35 is a success has been a top priority of the company for months, as I described in this profile in September with chief medical officer Tom Reynolds.The company said another antibody it’s developing, SGN-40 or dacetuzumab, caused complete or partial tumor shrinkage in about 10 percent of 38 patients in a clinical trial.The SGN-40 drug is different from others on the market for lymphoma, like Genentech and Biogen Idec’s rituximab (Rituxan), because it’s designed to hit a different protein target called CD-40.